Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 975 results for death

  1. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (HTG253)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG253

  2. Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates (HTG158)

    Evidence-based recommendations on hybrid procedure for interim management of hypoplastic left heart syndrome in neonates. This involves placing bands around the branches of the pulmonary artery and inserting stents to keep the ductus arteriosus open.

    HealthTech guidance
    Published
    12 December 2007
    View recommendations

    Sections for HTG158

  3. Lumbar subcutaneous shunt (HTG41)

    Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.

    HealthTech guidance
    Published
    23 June 2004
    View recommendations

    Sections for HTG41

  4. Extracorporeal photopheresis for Crohn's disease (HTG182)

    Evidence-based recommendations on extracorporeal photopheresis for Crohn's disease. This involves collecting blood from the person, separating the white blood cells from the whole blood, treating with ultraviolet light and re-infusing into the person. The aim is to produce a generalised immune response against the cells that cause the inflammation.

    HealthTech guidance
    Published
    25 February 2009
    View recommendations

    Sections for HTG182

  5. Cryotherapy for malignant endobronchial obstruction (HTG89)

    Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.

    HealthTech guidance
    Published
    23 November 2005
    View recommendations

    Sections for HTG89

  6. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

    Technology appraisal guidance
    Published
    8 July 2022
    View recommendations

    Sections for TA808

  7. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

    Technology appraisal guidance
    Published
    11 September 2024
    View recommendations

    Sections for TA1003

  8. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    27 July 2016
    View recommendations

    Sections for TA400

  9. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    2 October 2014
    View quality statements

    Sections for QS71

  10. Irreversible electroporation for primary liver cancer (HTG532)

    Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.

    HealthTech guidance
    Published
    27 November 2019
    View recommendations

    Sections for HTG532

  11. Implanting a baroreceptor stimulation device for resistant hypertension (HTG387)

    Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.

    HealthTech guidance
    Published
    28 October 2015
    View recommendations

    Sections for HTG387

  12. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.

    Technology appraisal guidance
    Published
    8 August 2018
    View recommendations

    Sections for TA535

  13. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

    Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

    Evidence summary
    Published
    19 January 2016

  14. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 October 2014

  15. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

    Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.

    Technology appraisal guidance
    Published
    21 September 2022
    View recommendations

    Sections for TA825